loading page

Reoccurence of Takotsubo Cardiomyopathy Induced by Osimertinib: Case Report
  • +1
  • Yuko Fukuda,
  • Yoshitaka Kawa,
  • Akiko Nonaka,
  • Hideyuki Shiotani
Yuko Fukuda
Hyogo Cancer Center

Corresponding Author:[email protected]

Author Profile
Yoshitaka Kawa
Hyogo Cancer Center
Author Profile
Akiko Nonaka
Hyogo Cancer Center
Author Profile
Hideyuki Shiotani
Kobe Tokiwa University
Author Profile

Abstract

A patient with lung cancer was administrated osimertinib. She developed symptomatic heart failure due to Takotsubo-cardiomyopathy (TC). As her condition improved after discontinuing osimertinib, TC was thought to be caused by osimertinib. Re-occurrence of TC was seen after re-administraing half dose of osimernitib.
09 May 2022Submitted to Clinical Case Reports
12 May 2022Submission Checks Completed
12 May 2022Assigned to Editor
16 May 2022Reviewer(s) Assigned
04 Jun 2022Review(s) Completed, Editorial Evaluation Pending
12 Jun 2022Editorial Decision: Revise Minor
28 Jun 20221st Revision Received
04 Jul 2022Submission Checks Completed
04 Jul 2022Assigned to Editor
04 Jul 2022Review(s) Completed, Editorial Evaluation Pending
10 Jul 2022Reviewer(s) Assigned
31 Jul 2022Editorial Decision: Accept